InfuSystem Holdings, Inc.
Rank #16Capital ReturnINFU · NYSE · Healthcare
InfuSystem Holdings, Inc. (INFU) — Rank #16 by gross profitability (GP/assets 0.82) · ROE 11.2% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0001337013 · all metrics point-in-time as of the filing date.
About
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada.
Show moreShow less
It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers.
The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- infusystem.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$245.11M
P/E (annual)
39.2
P/S (annual)
1.7
P/B
4.1
P/OCF (annual)
10.0
Shareholder Yield
2.8%
Employees
461
Industry
Medical Devices
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
-0.8%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -2.8% — per-share value needs a total required return of -3.7% once share-count change is priced in.
vs. own 6-year median revenue growth: 7.3%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
-4.6%
r = 10% (base)
-0.8%
r = 12%
2.4%
Net debt / market cap: 7.6%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Earnings bubble check
Current margins may be above sustainable levels — a P/E based on peak earnings can overstate cheapness.
FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.82
Primary signal (Novy-Marx).
2nd of 17 SIC 3841 peers
Return on equity
11.2%
Gross margin
56.0%
15th of 17 SIC 3841 peers
Revenue growth (YoY)
6.4%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
9.3%
Revenue CAGR (5Y)
8.1%
Earnings CAGR (3Y)
616.7%
FCF CAGR (3Y)
13.0%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.65
8th of 16 SIC 3841 peers (best = lowest)
Current ratio
2.50×
10th of 17 SIC 3841 peers
Quick ratio
1.84×
Net cash
-$19.46M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$23.85M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
2.60
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
3.0%
Stock-based comp intensity.
Piotroski F-Score
F-Score
8 / 9
Fundamental-strength score (0-9).